Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04926571 · ClinicalTrials.gov registry record
Dexamethasone and COVID-19 Inpatient Mortality
A clinical trial, sponsored by Aetion.
- Completed
- Registry status
- 14,105
- Enrollment target
NCT04926571: Completed study, sponsored by Aetion.
NCT04926571 is a clinical trial that has completed, run by Aetion. The registered enrollment target is 14,105 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04926571 has completed, sponsored by Aetion.
- COMPLETED
- Registry status
- 14,105 participants
- Enrollment target
Study Summary
The study aims to assess the effectiveness of dexamethasone initiation to reduce the risk of inpatient mortality within 28 days among US patients hospitalized with COVID-19 diagnosis or SARS-CoV-2 infection, overall and stratified by COVID-19 severity subgroups.
Primary Outcome
Mortality within 28 days of admission
Interventions
- DRUG Dexamethasone Oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,105 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2021-08-27 |
What the finished NCT04926571 record still lists
NCT04926571 is an observational study that tracks outcomes without assigning an intervention. Its 14,105 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Dexamethasone Oral is the first listed.
NCT04926571 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04926571 about?
NCT04926571 is a clinical study titled "Dexamethasone and COVID-19 Inpatient Mortality". The study aims to assess the effectiveness of dexamethasone initiation to reduce the risk of inpatient mortality within 28 days among US patients hospitalized with COVID-19 diagnosis or SARS-CoV-2 infection, overall and stratified by COVID-19 severity subgroups.
What is the current status of trial NCT04926571?
This trial is currently completed. The enrollment target is 14,105 participants. The study started on 2020-04-01. Estimated completion is 2021-08-27.
What interventions are being tested in trial NCT04926571?
The interventions under investigation include: Dexamethasone Oral (DRUG).
Who is sponsoring clinical trial NCT04926571?
This trial is sponsored by Aetion, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05591066 · 14,400 participants · NA
The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now
- NCT06058767 · 13,764 participants · NA
Preschool Hearing Screening
- NCT05359016 · 14,600 participants · NA
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
- NCT05141396 · 13,400 participants · NA
Telehealth-Enabled, Real-time Audit and Feedback for Clinician AdHerence (TEACH)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI